Relaxin-2 (Serelaxin) vs BPC-157 — Peptide Comparison

Relaxin-2 (Serelaxin) vs BPC-157 — Peptide Comparison Relaxin-2 (Serelaxin) vs BPC-157 — compare dosing, benefits, safety profiles, side effects, and how they stack. See which peptide is right for you. At a Glance Dose Range Relaxin-2 (Serelaxin) 1–10 mcg BPC-157 250–500 mcg Frequency Once daily Administration Intravenous (IV) infusion Subcutaneous injection Cycle Length 8-12 weeks 4-6 weeks Onset Speed Moderate (1-2 weeks) Evidence Level Limited human trials Strong preclinical (extensive animal studies) Efficacy Cardiovascular Function Heart Failure Support Acute Medical Management Primary Benefit Secondary Benefit Additional Benefit Technical Data Molecular Formula C256H408N74O74S8 Molecular Weight 5,963 Da (Daltons) Half-Life Varies by route of administration Bioavailability CAS Number See PubChem for identifiers C62H98N16O22 1419.53 g/mol 4-6 hours ~100% (subcutaneous) 137525-51-0 Protocols standard 30 mcg/kg/day Continuous IV infusion 48 hours Weight-adjusted continuous IV infusion used across the RELAX-AHF programme for acute heart failure; improved dyspnea but did not reduce mortality in RELAX-AHF-2 [3][5]. Hospital administration only. starting 250 mcg 1-2 weeks A common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2]. 250-500 mcg Twice daily Commonly used range for tissue and tendon recovery in research practice [1][3]. advanced 500 mcg 6-8 weeks Upper end used in practice for more demanding acute injuries [1][3]. Applications Acute heart failure symptom management Relaxin-2 (Serelaxin) is particularly effective for individuals focused on acute heart failure symptom management. Research supports its use in this area. Cardiovascular recovery and support Relaxin-2 (Serelaxin) is particularly effective for individuals focused on cardiovascular recovery and support. Research supports its use in this area. Hospital-based therapeutic interventions Relaxin-2 (Serelaxin) is particularly effective for individuals focused on hospital-based therapeutic interventions. Research supports its use in this area. Tendon and ligament injuries Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair Gut healing IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue Muscle injuries Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression Joint problems Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties Post-surgical recovery Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms Safety Profile Common Hypotension (low blood pressure) - most common Tachycardia (increased heart rate) Headache Nausea Dizziness Peripheral edema (swelling) Increased creatinine levels Hyperkalemia (high potassium) Syncope (fainting) Atrial fibrillation Blood pressure checks every 2-4 hours during infusion Kidney function (creatinine and eGFR) Electrolytes, particularly potassium Heart rate and cardiac rhythm Urine output Serious Severe cardiovascular events Injection site redness Mild nausea Uncommon Fatigue Hot/cold sensations Allergic reaction Research Status FDA Status Research compound Safety Overview Serelaxin (recombinant relaxin-2) completed Phase III heart failure trials with favorable safety profile and cardiovascular benefit signals. Hypotension occurs in 20-25% of subjects requiring hemodynamic monitoring; no serious adverse events directly attributable to serelaxin beyond expected vasodilatory effects. Flushing and headaches mild and transient. No serious immunogenicity despite being recombinant human peptide; repeat dosing shows consistent response. Contraindications xSevere hypotension or hemodynamic instability xPregnancy (despite relaxin's natural role) xAcute kidney injury or severe renal dysfunction xRecent myocardial infarction (within 7 days) xUncontrolled arrhythmias BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions. xPregnancy xBreastfeeding xActive cancer xHistory of cancer Decision Guide Choose Relaxin-2 (Serelaxin) if... Acute heart failure symptom management Cardiovascular recovery and support Hospital-based therapeutic interventions Choose BPC-157 if... Injury recovery Post-surgery healing Chronic pain management Gut health